The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | The genomic definition of ultra-high-risk multiple myeloma
Jill Corre, PhD, The Cancer University Institute of Toulouse Oncopole, Toulouse, France, discusses the genomic criteria for defining ultra-high-risk multiple myeloma. This condition is characterized by specific genetic mutations, such as TP53 biallelic inactivation, biallelic deletion of 1p32, and certain t(4;14) translocations. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
